# Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

> **NCT04157140** · PHASE2 · UNKNOWN · sponsor: **Jinglong Chen** · enrollment: 48 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anlotinib
- **DEVICE:** TACE+RFA

## Key facts

- **NCT ID:** NCT04157140
- **Lead sponsor:** Jinglong Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-28
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-03-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157140, "Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04157140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*